Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohiko Harada

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Gastroenterology|June 9, 2005
Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspirationHideaki Kitoh, Shomei Ryozawa, Tomohiko Harada, et al.
Oncology|June 18, 2002
Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reactionTomohiko Harada, Kiwamu Okita, Kei Shiraishi, et al.
Bioorganic & Medicinal Chemistry|June 14, 2011
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl groupYasuyuki Kawaratani, Tomohiko Harada, Yoshiyuki Hirata, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2017
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosisLudwig Kappos, Douglas L Arnold, Amit Bar-Or, et al.
Plos One|February 2, 2013
Molecular analysis of precursor lesions in familial pancreatic cancerTatjana Crnogorac-Jurcevic, Claude Chelala, Sayka Barry, et al.
The Lancet. Neurology|August 21, 2016
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trialLudwig Kappos, Douglas L Arnold, Amit Bar-Or, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 21, 2025
Comparison of dose rounding and drug vial optimization for reducing anticancer drug wasteTomohiko Harada, Eiseki Usami, Takuya Aso, et al.
BMJ Open|September 14, 2023
Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapyOuki Kuniyoshi, Motohiko Sano, Yasuhiro Nakano, et al.
British Journal of Pharmacology|October 8, 2016
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia riskKunio Sugahara, Yasuhiro Maeda, Kyoko Shimano, et al.
BMC Pharmacology & Toxicology|October 7, 2020
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational studyReiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Gastroenterology|June 9, 2005
Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspirationHideaki Kitoh, Shomei Ryozawa, Tomohiko Harada, et al.
Oncology|June 18, 2002
Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reactionTomohiko Harada, Kiwamu Okita, Kei Shiraishi, et al.
Bioorganic & Medicinal Chemistry|June 14, 2011
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl groupYasuyuki Kawaratani, Tomohiko Harada, Yoshiyuki Hirata, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2017
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosisLudwig Kappos, Douglas L Arnold, Amit Bar-Or, et al.
Plos One|February 2, 2013
Molecular analysis of precursor lesions in familial pancreatic cancerTatjana Crnogorac-Jurcevic, Claude Chelala, Sayka Barry, et al.
The Lancet. Neurology|August 21, 2016
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trialLudwig Kappos, Douglas L Arnold, Amit Bar-Or, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 21, 2025
Comparison of dose rounding and drug vial optimization for reducing anticancer drug wasteTomohiko Harada, Eiseki Usami, Takuya Aso, et al.
BMJ Open|September 14, 2023
Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapyOuki Kuniyoshi, Motohiko Sano, Yasuhiro Nakano, et al.
British Journal of Pharmacology|October 8, 2016
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia riskKunio Sugahara, Yasuhiro Maeda, Kyoko Shimano, et al.
BMC Pharmacology & Toxicology|October 7, 2020
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational studyReiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, et al.
Pageof 3